GMP News - APIs and Excipients


EXCiPACT - A new Certification Scheme for Excipients has been launched

On 1st February, 2012; the IPEC Federation announced the successful launch of EXCiPACT - its new, voluntary international certification scheme designed and developed to assure cGMP and cGDP standards are being used in the manufacture and supply of pharmaceutical excipients. Please read more here.



Significant Administrative Changes in the New Revision of the Guideline on the ASMF Procedure

The latest revision of the Guideline on the Active Substance Master File Procedure mainly shows administrative changes supposed to harmonise the whole procedure and the communication between the ASMF holder and the Authorities. Read more here.



Extension of Directive 2003/94/EC to GMP for APIs - EC Commission publishes Concept Paper for Comment

The Directive on the prevention of the entry of falsified medicinal products into the legal supply chain obliges the EU Commission to adopt the guidelines and principles of good manufacturing practice for APIs by means of a delegated act in form of a directive. In a first step, the Commission has published a concept paper for comment. Read more here.



Inadequate Validation of Analytical Methods remains permanent Topic in Warning Letters to API Manufacturers

The use of not validated or inadequate analytical procedures and the lack of a GMP compliant qualification of analytical instruments - these are violations against basic GMP regulations in the analytical lab the FDA keeps on finding during inspections of API manufacturers. Read more about the analysis of API Warning Letters in the past fiscal year - here.



GMP non-Compliance causes further CEP Suspensions

The EDQM, the European Directorate for the Quality of Medicines and Healthcare has suspended a number of CEPs following a GMP inspection recently. For more information please click here.



Drug Master Files (DMF) - Recorded Webinar with FDA Dr Arthur B. Shaw

On Monday 14 November 2011, the FDA presented a webinar entitled "Introduction to the Drug Master File (DMF)". A recording of this webinar is now available.To see this webinar at no cost please click here



Anti-Counterfeiting Directive requires Import Certificate for the Import of APIs from Third Countries into the EU

Very soon third countries will only be allowed to export Active Pharmaceutical Ingredients (APIs) to the EU if an accompanying letter confirms that the exporting country fulfils certain requirements with regard to GMP regulations. This written statement is not necessary if the specific country was evaluated positively by the EU Commission before. Learn more about the first steps towards a new regulation which will become effective on 2 July 2013.



CEP Suspensions and Withdrawal due to GMP Deviations

The EDQM, the European Directorate for the Quality of Medicines and Healthcare, has suspended and withdrawn a number of Certificate of Suitability (CEP) between September and November 2011. Please read more here.



GHTF publishes Guidance on Globally Harmonised Identification of Medical Devices

On 16 September 2011, the Global Harmonisation Task Force (GHTF) published the final version of a guidance entitled "Unique Device Identification (UDI) System for Medical Devices".  What the purpose of this document is you can read here.



FDA's Current Position about Melamine Contamination in Pharmaceutical Excipients

A few years ago, the highly toxic substance melamine was discovered as illegal extender in pet food and milk products from China. As a result of a potential hazard for the patients' health, the FDA published a "Guidance for Industry" document on melamine contamination in pharmaceutical components. The current position of the FDA regarding the melamine analysis issue has been recently published. Read more here.



EMA publishes two advisory Documents addressing a Number of Questions about centralised Admission Procedures

The EMA has recently published two documents concerning the centralised application procedures for new, generic and hybrid medicinal products. How useful these documents are and where to find them can be read here.



EDQM gives Clarification concerning Stability Data for APIs within the Certification Procedure

The Guideline "Stability Testing of existing active substances and related finished products" (CPMP/QWP/122/02 rev1 corr) provides information about stability data required in a marketing authorisation dossier for monographed and non-monographed APIs. As the obligations of the API manufacturers hadn't been very clear, the EDQM decided to provide clarification. Read more.



New EMA Draft Guideline on Stability Data regarding Applications for Variations to a Marketing Authorisation

Because of the extensive reorganisation of applications for variations contained in the Variations Regulation from 2010, a revision of the "Guideline on stability testing for applications for variations to a marketing authorisation" became necessary. Read here, which stability testing data are required by regulatory authorities in case of applications for variations.



Warning of Potential Contamination with Toxic Plasticizer

The recent discovery about the fraudulent replacement of vegetal oils as emulsifiers with toxic plasticizers in the products of two Taiwanese companies has led both the FDA and the IPEC Europe to publish warning notifications. Read more here about the incident.



MPA Proposal: No GMP Certificate in Case of Violation of environmental Constraints

In a 46 page report, the Swedish Medical Products Agency (MPA) presents an initiative aiming to introduce environmental constraints into the EU GMP Guidelines. The reason for this is based on the near inexistence of environmental concerns in the countries where the manufacture of APIs is outsourced. Read more here about this initiative.


GMP Newsletter

Sign up for the free of charge newsletters.

Sign up now!

GMP Conferences by Topics